Monday, June 6, 2016

BRIEF-Galena Biopharma's GALE-301 well-tolerated based on primary analysis

* Galena Biopharma presents GALE-301 phase 1/2a primary

analysis at the American Society Of Clinical Oncology Annual

Meeting 2016

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)